Collaborate With An Experienced Bioconjugates Partner For Clinical To Commercial Manufacturing Success – A Focus On The MSAT Bioconjugate Group

By Charlotte Sornay, Ph.D., MSAT Associate Principal Scientist in Bioconjugates, Lonza, and Laurence Bonnafoux, Ph.D., Head of MSAT Bioconjugates, Lonza

As antibody-drug conjugates (ADCs) and bioconjugates grow increasingly popular across the biopharmaceutical industry, manufacturers must find adaptive solutions to produce them efficiently. Since the first ADC was approved in 2000 – Mylotarg by Pfizer – followed, later, by the approval of a 2nd generation of ADCs, technologies have evolved to offer ADCs with more stable linkers that are generated via site selective conjugation strategies, and thus offer improved therapeutic indexes. Following the rapid acceleration in ADC approval since 2019, more and more diverse bioconjugate molecules are entering the drug pipeline.

To meet demand, contract development and manufacturing organizations (CDMOs) are designing processes that produce high quantities of drugs with quality and meet customer’s accelerated timelines to commercial manufacturing. In many cases, these efficient platforms benefit from the influence of dedicated bioconjugate teams on the manufacturing life cycle. Download the full article to learn more about how the right bioconjugate development partner can provide specialized insight into process optimization, scale-up, and process validation.